Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00602641 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT00602641 · ClinicalTrials.gov record · last posted 2026-08-27

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

StatusActive, Not Recruiting
PhasePhase 3
Started2008-02-29
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This randomized phase III trial studies melphalan and prednisone with thalidomide to see how well it works compared to melphalan and prednisone together with lenalidomide in treating patients with newly diagnosed multiple myeloma. Drugs used in chemotherapy, such as melphalan and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Thalidomide and lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. It is not yet known whether melphalan and prednisone are more effective when given together with thalidomide or lenalidomide in treating multiple myeloma.

Protocol amendment history 1 change detected by DataLookout

2026-04-30
Completion pushed: 2026-02-22 → 2027-02-20
Trial Details
NCT Number NCT00602641
Lead Sponsor National Cancer Institute (NCI)
Conditions Multiple Myeloma
Enrollment 306 participants
Start Date 2008-02-29
Primary Completion 2014-01-18 (estimated)
Study Completion 2027-02-20 (estimated)
Updated on ClinicalTrials.gov 2026-08-27